18 unchanged sentences
The stockholder returns shown on the graph below are based on historical results and are not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder returns.
−Removed: 12/8/17 12/29/17 3/31/18 6/30/18 9/30/18 12/31/18 3/31/19 6/30/19 9/30/19 12/31/19 3/31/20 6/30/20 9/30/20 12/31/20
−Removed: Denali Therapeutics Inc.
−Removed: $ 100.00 $ 87.03 $ 109.57 $ 84.86 $ 120.98 $ 114.97 $ 129.22 $ 115.53 $ 85.25 $ 96.94 $ 97.44 $ 134.56 $ 199.39 $ 466.11
−Removed: NASDAQ Composite Index 100.00 101.37 103.99 110.87 119.09 98.49 115.04 119.50 119.71 134.63 115.84 151.69 168.74 195.11
−Removed: NASDAQ Biotechnology Index 100.00 102.71 102.77 105.93 117.79 93.61 108.16 105.72 96.61 117.11 105.08 133.35 132.25 148.06
Recent Sales of Unregistered Securities
−Removed: On September 22, 2020, we issued and sold 13,310,243 shares of our common stock to Biogen for an aggregate purchase price of $465.0 million pursuant to the terms of a common stock purchase agreement with BIMA and in connection with the Biogen Collaboration Agreement.
−Removed: No underwriters were involved in the sale and the book entry position representing the securities sold and issued contain legends restricting transfer of the securities without registration under the Securities Act or an applicable exemption from registration.
−Removed: The offer, sale and issuance of the securities described above was exempt from registration under the Securities Act under Section 4(a)(2) of the Securities Act as a transaction by an issuer not involving a public offering.
−Removed: The recipient of securities in this transaction acquired the securities for investment only and not with a view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the securities issued in this transaction.
−Removed: The recipient of securities in this transaction was an accredited person and had adequate access, through employment, business or other relationships, to information about the registrant.
+Added: There were no sales of unregistered securities during the period covered by this Annual Report on Form 10-K, other than those previously reported in a Quarterly Report on Form 10-Q or in a Current Report on Form 8-K.
Use of Proceeds from Registered Securities
−Removed: On December 7, 2017, our Registration Statement on Form S-1 (File No.
−Removed: 333-221522) was declared effective by the SEC for our initial public offering of common stock.
−Removed: We started trading on The NASDAQ Global Select Market on December 8, 2017, and the transaction formally closed on December 12, 2017.
−Removed: In connection with the initial public offering, we sold an aggregate of 15,972,221 shares of common stock, including 2,083,333 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $18.00 per share.
−Removed: The aggregate offering price for shares sold in the offering was $287.5 million.
−Removed: The joint book-running managers for the initial public offering were Goldman, Sachs & Co.
−Removed: LLC, Morgan Stanley & Co.
−Removed: LLC, and J.P.
−Removed: Morgan Securities LLC.
−Removed: After deducting underwriting discounts, commissions and offering expenses paid or payable by us of approximately $23.2 million, the net proceeds from the offering were approximately $264.3 million.
−Removed: No offering expenses were paid or are payable, directly or indirectly, to our directors or officers, to persons owning 10.0% or more of any class of our equity securities or to any of our affiliates.
−Removed: There has been no material change in the planned use of proceeds from our initial public offering as described in our final prospectus filed with the SEC on December 8, 2017 pursuant to Rule 424(b)(4).
−Removed: We invested the funds received in short-term, interest-bearing investment-grade securities and government securities.
In January 2020, we sold 9.0 million shares of common stock (inclusive of shares sold pursuant to an overallotment option granted to the underwriters in connection with the offering) through an underwritten public offering at a price of $23.00 per share for aggregate net proceeds of approximately $193.9 million .
4 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.